Mamta Parikh

Trials

Studies that name Mamta Parikh as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:53 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06173362 · Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

  University of California, Davis · recruiting · Advanced Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8 · principal investigator
• Ph1
  NCT06173349 · PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

  University of California, Davis · recruiting · Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8 · principal investigator
• N/A
  NCT06101290 · Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

  University of California, Davis · recruiting · Prostate Cancer, Oligoprogressive, Urothelial Carcinoma · principal investigator
• Ph1
  NCT05843448 · IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

  University of California, Davis · active not recruiting · High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8 · principal investigator
• Ph1/Ph2
  NCT04856189 · Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

  Mamta Parikh · terminated · Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma · principal investigator
• Ph1
  NCT04491942 · Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

  National Cancer Institute (NCI) · active not recruiting · Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma · principal investigator
• Ph1
  NCT03123978 · Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

  University of California, Davis · completed · Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer · principal investigator
• Ph2
  NCT02807805 · Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

  Mamta Parikh · active not recruiting · Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 21:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• CTSA Research Education R25 at University of California at Davis: Student Physician-Scientist Early Research Experiences (SPHERE) Academy
  R25TR006133 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2026 · $107,974 awarded in 2026
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Integrated Cancer Biology Program
  P30CA093373 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Wolf-Dietrich Heyer · fiscal years 2009 to 2026
  Named on NCT06173362, NCT06173349, NCT05843448, NCT04856189, NCT03123978, NCT02807805
• Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
  UM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026
  Named on NCT04491942